# Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Study · id `cardio:ct-nct06858319` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06858319](<https://clinicaltrials.gov/study/NCT06858319>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06858319

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.

## Technical summary

Registry record NCT06858319. Allocation not applicable; no masking; primary purpose treatment. Start 2025-07-28 (actual); primary completion 2031-06-25 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 220 participants (planned count; ClinicalTrials.gov record NCT06858319, source copy `cardio:ctgov-nct06858319-2026-08-17`, retrieved 2026-10-26)
- Started: 2025-07-28 (actual) (ClinicalTrials.gov record NCT06858319, source copy `cardio:ctgov-nct06858319-2026-08-17`, retrieved 2026-10-26)
- Primary completion: 2031-06-25 (anticipated) (ClinicalTrials.gov record NCT06858319, source copy `cardio:ctgov-nct06858319-2026-08-17`, retrieved 2026-10-26)
- Completion: 2031-06-25 (anticipated) (ClinicalTrials.gov record NCT06858319, source copy `cardio:ctgov-nct06858319-2026-08-17`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Canada; Malaysia; Mexico; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT06858319, source copy `cardio:ctgov-nct06858319-2026-08-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06858319-2026-08-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Condition: Kidney Diseases
- Condition: Kidney Diseases, Chronic
- Condition: Urological Diseases
- Condition: Glomerulonephritis
- Condition: Glomerular Disease
- Condition: Glomerulonephritis, IGA
- Condition: Glomerulopathy
- Condition: Immunoglobulin Disease
- Intervention (Drug): zigakibart
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 44a1621ad617307df6c171327efcc47f40aad5d5dece26413bf276a71c304e03
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
